Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 8/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708808 | 0.88 | CNR2 (0.53) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL4471731 | 0.84 | CNR2 (0.58) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL4472734 | 0.82 | CNR2 (0.59) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL14495478 | 0.79 | P2RX7 (0.45) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL4487562 | 0.77 | CNR2 (0.55) | TACR1MGLLP2RX7CNR2GRM2 | |
| SCHEMBL4697346 | 0.76 | CNR2 (0.56) | MLNRTACR1CYP3A4P2RX7CNR2 | |
| SCHEMBL4475198 | 0.75 | CNR2 (0.53) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL4478348 | 0.75 | CNR2 (0.53) | TACR1MGLLP2RX7CNR2TACR2 | |
| SCHEMBL4475991 | 0.75 | CNR2 (0.58) | CNR2 | |
| SCHEMBL4467170 | 0.74 | CNR2 (0.54) | TACR1MGLLP2RX7CNR2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | MLNR 676/4885TACR1 203/4885CYP3A4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.